---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-064792"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:57:51.998016+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Korro Bio CFO Vineet Agarwal returns from medical leave; Oliver Dolan named principal accounting officer

## Summary
- CFO Vineet Agarwal reappointed as principal financial officer effective March 27, ending temporary medical leave since Feb 11.
- CEO Ram Aiyar ceases interim CFO duties; remains President and CEO.
- Oliver Dolan, SVP Finance, appointed principal accounting officer; granted 20,000-share stock option at closing price.
- Option grant effective April 1, 2025; standard indemnification agreement entered.

## SEC filing metadata
- accession: 0001193125-25-064792
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/d937220d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-064792
- JSON: https://secwatch.observer/filing/0001193125-25-064792.json
- Plain text: https://secwatch.observer/filing/0001193125-25-064792.txt

## Key facts
- Executive change
  Vineet Agarwal was appointed as Chief Financial Officer at Korro Bio, Inc..
  - Action: reappointed
  - Role: Chief Financial Officer
  source text: Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm
- Executive change
  Oliver Dolan was appointed as Principal Accounting Officer at Korro Bio, Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: the Company’s Board of Directors appointed Mr. Oliver Dolan, age 42, current Senior Vice President, Finance, to serve as the Company’s principal accounting officer effective March 27, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm
- Executive change
  Ram Aiyar changed role as President and Chief Executive Officer at Korro Bio, Inc..
  - Action: no longer serving
  - Role: President and Chief Executive Officer
  source text: Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.